Tag Archives: BIO Investor Forum

Resistance is Futile – SuperDrugs for SuperBugs

800px-Acinetobacter_baumannii

“MRSA’s kill 100,000 people a year, more than AIDS,” said Mark Leuchetenberger, President and CEO, Rib-X Pharmaceuticals, Inc. With new superbugs on the rise and new superdrugs continuing to decline, the antibacterial drug discovery market is anyone’s for the taking. Attendees of the 10th Annual BIO Investor Forum participating in the Infectious Disease Therapeutic Workshop heard from an engaging panel that seemed to agree the economics of this category are driven by two things: society expects Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Developing Cancer Therapies and Diagnostics: 4 Pieces of Advice

oncology

Insights in to the molecular and genetic basis of disease are driving new product and therapeutic opportunities while changing the treatment paradigm for many cancers. The use of companion diagnostics in oncology may play a role in optimizing and expediting the development of targeted therapies for many cancers and other conditions. Focusing on these new markets, a panel of industry executives and investors at the 2011 BIO Investor Forum discussed some of the most compelling Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

Multiple Assets Diversify the Deal

Partnering Meeting

With a recent surge in pharma companies collaborating earlier on with small biotech companies, discovery stage partnering deals are becoming increasingly popular.  Striking a discovery stage deal can be extremely beneficial for both parties in today’s environment – pharma gets to fill its ever elusive R&D pipeline as patent expirations loom, and the small biotech struggling to raise money to stay alive gets the capital infusion necessary to stay in play. Panelists in the “Broad Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Public Exits and Virtual Biotechs – Dreams or Reality?

Here at the 10th Annual BIO Investor Forum, investors and CEOs are debating “all the options” for private companies. The first panel of the conference explored the backdoor entrance into public markets as chilly winds continue to blow through the latest IPO window. For the lunch plenary, panelists examined the option to go virtual and make capital efficiency a reality. Reverse Mergers It is no secret that the IPO market for biotechs has been tough. Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Reverse Mergers: A Company is Ready to Go Public, or it’s Not

The latest IPO window has stalled. There have been five IPO withdrawals since June and around 30 since 2005. Global macro events are threatening to completely shut it. Reverse mergers have become an increasingly popular option with eight transactions in the last year. Unfortunately, 47 percent of reverse mergers have decreased in value post-close since 2008. At the 2011 BIO Investor Forum, a panel of experts examined the current financing environment and what private executive Read More >

Business of Biotech  |  2 Comments  |  Email This Post
Tags: , , , ,